Protein Binding Assays Market Size, Share, Growth Analysis, By Technology(Ultracentrifugation, Equilibrium Dialysis), By Product & Services(Instrument, Kits & Reagents), By End-use Outlook(Contract Research Organizations, Pharmaceutical & Biotechnology Companies), By Region(North America, Europe) - Industry Forecast 2024-2031

The market for Protein Binding Assays was estimated to be valued at US$ XX Mn in 2021.

The Protein Binding Assays Market is estimated to grow at a CAGR of XX% by 2028.

The Protein Binding Assays Market is segmented on the basis of Technology, Product & Services, End-use Outlook, Region.

Based on region, the Protein Binding Assays Market is segmented into North America, Europe, Asia Pacific, Middle East & Africa and Latin America.

The key players operating in the Protein Binding Assays Market are as well as CROs are engaged in offering protein binding services, contributing to the large revenue share of the services segment in 2018. Companies such as Eurofins Scientific; Cyprotex; Charles River Laboratories; Sekisui XenoTech, LLC; and many others are involved in providing services related to protein binding assays., Instruments segment is projected to witness lucrative growth in the near future due to user-friendly instruments and availability of automated systems for detection of protein binding. For example, Rapid Equilibrium Dialysis system by Thermo Fisher is convenient for laboratories using radioactive materials as this system makes use of disposable inserts and base plate., End-use Insights, In terms of revenue, pharmaceutical & biotechnology companies emerged as the dominant segment in 2018. This is because companies occupy a major share of the pharma production and are making significantly high investments on preclinical testing stages of drug discovery. In addition, this industry is marked by the presence of large, well-established players such as Roche and Merck that are involved in enhancement of their R&D activities to maintain their market position., A large number of new CROs focused on developing therapeutics are entering the market to capitalize on the potential avenues in the biopharmaceutical industry. Moreover, the demand for CROs is increasing owing to the cost benefits associated with outsourcing pharmaceutical manufacturing and quality control steps. These factors drive revenue generation the in CROs segment., Regional Insights, North America accounted for the largest share in the protein binding assays market with major contribution from the U.S. Local presence of KEY PLAYERS and increased funding from public & private entities have augmented drug discovery & development. Availability of grants from public agencies such as the National Institute of Health and the Defense Advanced Research Projects Agency is encouraging research activities in the field of drug discovery., Asia Pacific is predicted to witness the fastest growth over the forecast period due to several initiatives undertaken by regulatory agencies to revolutionize drug discovery & development programs in this region. A number of conferences on pharma research, such as 20th Asia Pacific Pharma Congress held in April 2019 in Japan, also boost regional growth., Furthermore, emerging economies in Asia Pacific region are preferred by many pharmaceutical companies owing to presence of large patient population, operational efficiencies, and low costs associated with development of therapeutics., KEY MARKET SEGMENTS, By Technology , Ultracentrifugation, Equilibrium Dialysis, Ultrafiltration, Surface Plasmon Resonance, Other Technologies, By Product & Services , Instrument, Kits & Reagents, Services, By End-use Outlook , Contract Research Organizations, Pharmaceutical & Biotechnology Companies, Other End-Use, By Region, North America, Europe, Asia Pacific, Latin America, MEA, KEY PLAYERS, Thermo Fisher Scientific, Inc., Charles River, Sovicell GMBH, Absorption Systems LLC, GE Healthcare, Eurofins Scientific, 3B Pharmaceuticals, Creative Biolabs, Evotec (Cyprotex), Bioduro.